<DOC>
	<DOCNO>NCT01227278</DOCNO>
	<brief_summary>To evaluate effect drug moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) Adults .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness MEDI-563 Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>To evaluate effect multiple subcutaneous ( SC ) dose benralizumab ( MEDI 563 ) rate moderate-to-severe annualized incidence rate moderate severe acute exacerbation chronic obstructive pulmonary disease ( AECOPD ) adult subject moderate-to-severe COPD exhibit eosinophilia ( great equal [ &gt; = ] 3.0 percent [ % ] sputum eosinophilia previous 12 month Screening ) sputum compare placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Subjects age 4085 year time Screening Written informed consent obtain subject prior perform protocol related procedure Documented history 1 Annualized Incidence Rate Moderate Severe Acute Exacerbations Chronic Obstructive Pulmonary Disease ( AECOPD ) Current smoker exsmoker tobacco history great equal ( &gt; = ) 10 packyears Adequate contraception screen end trial Able read write . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Pregnant , breastfeeding , lactate woman Known history allergy reaction component investigational product formulation History anaphylaxis biologic therapy Donation transfusion blood , plasma platelet within past 3 month prior Screening Other significant pulmonary disease opinion investigator medical monitor , might compromise interpretation study Fever great ( &gt; ) 37.0 degree Centigrade ( 98.6 degree Fahrenheit ) Screening Receipt novel investigational medicinal product within 3 month first dose investigational product study end study Seropositive hepatitis A , hepatitis B surface antigen , hepatitis C , human immunodeficiency virus 1or 2 ( HIV1 HIV 2 ) History alcohol drug abuse within past year require treatment investigator felt medical monitor felt would compromise study data interpretation Past current malignancy within past 5 year except adequately treat noninvasive basal cell squamous cell carcinoma skin cervical carcinoma situ treat apparent success 1 year prior Screening Subjects participate , schedule , intensive COPD rehabilitation program ( subject maintenance phase rehabilitation program eligible take part ) Current diagnosis asthma accord Global Initiative Asthma guideline Previous treatment MEDI563 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Benralizumab</keyword>
	<keyword>MEDI-563</keyword>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
</DOC>